The facts are sourced from an S-4 registration statement filed with the SEC via EDGAR, published on November 14, 2023. An S-4 is the filing type used to register securities issued in connection with a merger, consistent with the stock-for-stock structure of this deal. The current status of the transaction is pending regulatory review.
Perella Weinberg Partners L.P. is identified as the lead financial advisor to SomaLogic, the target. The source sentence is a consent letter excerpt stating: "We hereby consent to the inclusion of our opinion dated October 4, 2023 appearing as Annex C to, and the reference to such opinion letter under the headings 'Prospectus Summary, Opinion of SomaLogic's Financial Advisor' and 'The Merger, Opinion of SomaLogic Financial Advisor' in, the Registration Statement on Form S-4 of Standard BioTools Inc. and in the Joint Proxy Statement/Prospectus of Standard BioTools Inc. and SomaLogic, Inc." This confirms Perella Weinberg's role included rendering a fairness opinion to SomaLogic dated October 4, 2023. No financial advisor to Standard BioTools, the acquirer, is identified in the facts provided.
No legal advisors were extracted for this transaction in the available facts block.
Beyond the classification of this transaction as a stock-for-stock merger, no further detail on the exchange ratio or other specific consideration terms is included in the facts provided.
Several items are not disclosed in this record: the transaction value is not stated, no financial advisor to the acquirer is identified, no legal advisors to either side are identified, the exchange ratio is not specified, and no expected closing date is given beyond the pending-regulatory status.